Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

1.

Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.

Freedland SJ, Sutter ME, Dorey F, Aronson WJ.

Urology. 2003 Feb;61(2):365-9.

PMID:
12597949
[PubMed - indexed for MEDLINE]
2.

No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.

Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA.

Urology. 2004 Mar;63(3):528-31. Review.

PMID:
15028451
[PubMed - indexed for MEDLINE]
3.

Markers and meaning of primary treatment failure.

Swindle PW, Kattan MW, Scardino PT.

Urol Clin North Am. 2003 May;30(2):377-401. Review.

PMID:
12735513
[PubMed - indexed for MEDLINE]
4.

[PSA and follow-up after treatment of prostate cancer].

Benchikh El Fegoun A, Villers A, Moreau JL, Richaud P, Rebillard X, Beuzeboc P.

Prog Urol. 2008 Mar;18(3):137-44. doi: 10.1016/j.purol.2007.12.010. Epub 2008 Apr 18. Review. French.

PMID:
18472065
[PubMed - indexed for MEDLINE]
5.

How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure.

Jhaveri FM, Klein EA.

Semin Urol Oncol. 1999 Aug;17(3):130-4. Review.

PMID:
10462315
[PubMed - indexed for MEDLINE]
6.

[PSA rise after radical prostatectomy].

Wirth M, Fröhner M.

Urologe A. 2000 Jan;39(1):3-8. Review. German.

PMID:
10663189
[PubMed - indexed for MEDLINE]
7.

Rising prostate specific antigen after radical prostatectomy: a case based review.

Nasr R, Goldenberg SL.

Can J Urol. 2001 Aug;8(4):1306-13. Review.

PMID:
11564273
[PubMed - indexed for MEDLINE]
8.

[Biochemical recurrence criteria after radical prostatectomy. Natural history of the disease].

Planas J, Morote J.

Arch Esp Urol. 2012 Jan-Feb;65(1):4-11. Review. Spanish.

PMID:
22318173
[PubMed - indexed for MEDLINE]
9.

Observation/delayed treatment for rising PSA after radical prostatectomy: pros and cons.

Ruffion A, Valignat C, Champetier D, Lopez JG, Perrin P.

Semin Urol Oncol. 1999 Aug;17(3):135-40. Review.

PMID:
10462316
[PubMed - indexed for MEDLINE]
10.

What does prostate-specific antigen recurrence mean?

Pound CR, Partin AW.

Curr Urol Rep. 2000 May;1(1):28-35. Review.

PMID:
12084338
[PubMed - indexed for MEDLINE]
11.

[Laparoscopic lymphadenectomy. Current indications].

Rioja Sanz C, Blas Marín M, Rioja Sanz L.

Arch Esp Urol. 2002 Jul-Aug;55(6):667-78. Review. Spanish.

PMID:
12224165
[PubMed - indexed for MEDLINE]
12.

Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence.

Suardi N, Briganti A, Salonia A, Rigatti P.

Curr Opin Urol. 2011 May;21(3):237-40. doi: 10.1097/MOU.0b013e328344e4c4. Review.

PMID:
21427585
[PubMed - indexed for MEDLINE]
13.

[High-risk clinically localised prostate cancer].

Rozet F, Cornu JN, Cussenot O, Fromont G, Hennequin C.

Bull Cancer. 2010 Dec;97(12):1517-36. doi: 10.1684/bdc.2010.1228. Review. French.

PMID:
21220228
[PubMed - indexed for MEDLINE]
14.

Management of patients with rising prostate-specific antigen after radical prostatectomy.

Laufer M, Pound CR, Carducci MA, Eisenberger MA.

Urology. 2000 Mar;55(3):309-15. Review. No abstract available.

PMID:
10699599
[PubMed - indexed for MEDLINE]
15.

Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies.

Scosyrev E, Tobis S, Donsky H, Wu G, Joseph J, Rashid H, Messing E.

BJU Int. 2013 Mar;111(3 Pt B):E71-7. doi: 10.1111/j.1464-410X.2012.11527.x. Epub 2012 Sep 27. Review.

PMID:
23017100
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk